Protalix announces repayment of outstanding senior secured convertible notes

Protalix BioTherapeutics has repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Promissory Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.